A novel long-term intravenous combined with local treatment with human amnion-derived mesenchymal stem cells for a multidisciplinary rescued uremic calciphylaxis patient and the underlying mechanism
Lianju Qin,Jing Zhang,Yujie Xiao,Kang Liu,Yugui Cui,Fangyan Xu,Wenkai Ren,Yanggang Yuan,Chunyan Jiang,Song Ning,Xiaoxue Ye,Ming Zeng,Hanyang Qian,Anning Bian,Fan Li,Guang Yang,Shaowen Tang,Zhihong Zhang,Juncheng Dai,Jing Guo,Qiang Wang,Bin Sun,Yifei Ge,Chun Ouyang,Xueqiang Xu,Jing Wang,Yaoyu Huang,Hongqing Cui,Jing Zhou,Meilian Wang,Zhonglan Su,Yan Lu,Di Wu,Jingping Shi,Wei Liu,Li Dong,Yinbing Pan,Baiqiao Zhao,Ying Cui,Xueyan Gao,Zhanhui Gao,Xiang Ma,Aiqin Chen,Jie Wang,Meng Cao,Qian Cui,Li Chen,Feng Chen,Youjia Yu,Qiang Ji,Zhiwei Zhang,Mufeng Gu,Xiaojun Zhuang,Xiaolin Lv,Hui Wang,Yanyan Pan,Ling Wang,Xianrong Xu,Jing Zhao,Xiuqin Wang,Cuiping Liu,Ningxia Liang,Changying Xing,Jiayin Liu,Ningning Wang
DOI: https://doi.org/10.1093/jmcb/mjac010
2022-02-10
Journal of Molecular Cell Biology
Abstract:Abstract Calciphylaxis is a rare disease characterized histologically by microvessel calcification and microthrombosis, with high mortality and no proven therapy. Here, we reported a severe uremic calciphylaxis patient with progressive skin ischemia, large areas of painful malodorous ulcers, and mummified legs. Because of the worsening symptoms and signs refractory to conventional therapies, treatment with human amnion-derived mesenchymal stem cells (hAMSCs) was approved. Pre-clinical release inspections of hAMSCs, efficacy, and safety assessment including cytokine secretory ability, immunocompetence, tumorigenicity, and genetics analysis in vitro were introduced. We further performed acute and long-term hAMSC toxicity evaluations in C57BL/6 mice and rats, abnormal immune response tests in C57BL/6 mice, and tumorigenicity tests in neonatal Balbc-nu nude mice. After the pre-clinical research, the patient was treated with hAMSCs by intravenous and local intramuscular injection and external supernatant application to the ulcers. When followed up to 15 months, the blood-based markers of bone and mineral metabolism improved, with skin soft tissue regeneration and a more favorable profile of peripheral blood mononuclear cells. Skin biopsy after 1-month treatment showed vascular regeneration with mature non-calcified vessels within the dermis, and 20 months later, the re-epithelialization restored the integrity of the damaged site. No infusion or local treatment-related adverse events occurred. Thus, this novel long-term intravenous combined with local treatment with hAMSCs warrants further investigation as a potential regenerative treatment for uremic calciphylaxis with effects of inhibiting vascular calcification, stimulating angiogenesis and myogenesis, anti-inflammatory and immune modulation, multi-differentiation, re-epithelialization, and restoration of integrity.
cell biology